North Dallas Bank & Trust Co. Invests $593,000 in Medtronic PLC $MDT

North Dallas Bank & Trust Co. bought a new position in Medtronic PLC (NYSE:MDT) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 6,172 shares of the medical technology company’s stock, valued at approximately $593,000.

Several other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Medtronic by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 128,961,343 shares of the medical technology company’s stock worth $12,388,027,000 after acquiring an additional 1,888,381 shares in the last quarter. State Street Corp increased its position in shares of Medtronic by 1.0% in the third quarter. State Street Corp now owns 60,460,537 shares of the medical technology company’s stock worth $5,800,550,000 after acquiring an additional 625,992 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Medtronic by 2.7% in the fourth quarter. JPMorgan Chase & Co. now owns 53,616,694 shares of the medical technology company’s stock worth $5,150,420,000 after acquiring an additional 1,419,730 shares in the last quarter. Capital Research Global Investors increased its position in shares of Medtronic by 12.6% in the fourth quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock worth $3,321,101,000 after acquiring an additional 3,880,174 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Medtronic by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 27,879,481 shares of the medical technology company’s stock worth $2,665,832,000 after acquiring an additional 231,919 shares in the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Healthcare is outperforming as investors rotate away from tech, which supports Medtronic as a defensive name in a stronger sector. As Tech Stocks Slide, The Healthcare Sector Shines. Why Some Experts Say They Like This Defensive Play
• Positive Sentiment: Medtronic won FDA clearance for its updated Nellcor pulse oximetry system, a technology update aimed at improving reliability across diverse patients and care settings. Medtronic gets FDA nod for updated pulse oximetry system
• Positive Sentiment: The company earned CE mark approval for its Stealth AXiS robot platform in ENT surgery, opening the door to broader use in Europe. Medtronic earns CE mark for Stealth AXiS robot platform in ENT surgery
• Positive Sentiment: Medtronic also received FDA clearance for an upgraded Nellcor pulse oximetry system with an intelligent processor, reinforcing momentum in its monitoring portfolio. Medtronic wins FDA clearance for Nellcor pulse oximetry system with intelligent processor
• Positive Sentiment: Analyst commentary has been increasingly constructive, with some writers arguing Medtronic may be one of the better buys in healthcare after its recent results showed solid growth. Why Medtronic Stock May Have Just Become the Best Buy in the Entire Healthcare Sector
• Neutral Sentiment: Medtronic’s EVP Harry Skip Kiil sold 4,189 shares, a routine insider transaction that may modestly weigh on sentiment but does not by itself signal a major change in outlook. Harry Skip Kiil insider transaction
• Neutral Sentiment: MarketWatch noted the stock underperformed some peers despite gains, suggesting investors are still comparing Medtronic’s move against stronger healthcare competitors. Medtronic PLC stock underperforms Tuesday when compared to competitors despite daily gains

Medtronic Stock Performance

MDT stock opened at $81.93 on Wednesday. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $105.19 billion, a price-to-earnings ratio of 21.96, a P/E/G ratio of 1.96 and a beta of 0.58. Medtronic PLC has a 12 month low of $73.31 and a 12 month high of $106.33. The firm has a 50 day moving average of $81.21 and a two-hundred day moving average of $91.74.

Medtronic (NYSE:MDT) last posted its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, topping the consensus estimate of $1.54 by $0.01. The company had revenue of $9.81 billion during the quarter, compared to the consensus estimate of $9.62 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.61%. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.62 earnings per share. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, equities analysts anticipate that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 17th. Shareholders of record on Friday, June 26th will be given a $0.72 dividend. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 annualized dividend and a yield of 3.5%. The ex-dividend date of this dividend is Friday, June 26th. Medtronic’s payout ratio is presently 76.14%.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the sale, the executive vice president directly owned 37,227 shares of the company’s stock, valued at $2,994,539.88. The trade was a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.26% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. TD Cowen reissued a “buy” rating and issued a $119.00 target price on shares of Medtronic in a research report on Thursday, June 4th. Evercore set a $106.00 price objective on shares of Medtronic and gave the company an “outperform” rating in a research report on Thursday, April 9th. Wall Street Zen lowered shares of Medtronic from a “buy” rating to a “hold” rating in a research note on Saturday, April 11th. The Goldman Sachs Group dropped their price objective on shares of Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a research note on Thursday, June 4th. Finally, Mizuho dropped their price objective on shares of Medtronic from $120.00 to $100.00 and set an “outperform” rating on the stock in a research note on Wednesday, June 3rd. Seventeen investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $99.00.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).